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Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified
by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV
non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now
represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate
real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward
towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
British Journal of Cancer (2021) 125:1210–1216; https://doi.org/10.1038/s41416-021-01407-9
Large cell neuroendocrine lung carcinoma (LCNEC) is a rare lung
cancer subtype for which progress in management has fallen
behind the significant developments seen in non-small cell lung
cancer (NSCLC) using targeted therapies and checkpoint inhibi-
tors.1 The World Health Organisation classify LCNEC as a
neuroendocrine carcinoma, while its management and clinical
phenotype have often been considered to be consistent with
small cell lung carcinoma (SCLC).2 Two key clinical differences
from SCLC are that (i) it is more likely to present with early stage
disease (~25% of cases), and (ii) primary lesions are more likely to
be peripheral.3 More in keeping with SCLC, patient survival at
stage IV is generally poor (median < 1 year), a figure that
represents a paucity of preclinical research and clinical trials in
this area; a striking contrast to ALK-rearranged NSCLC, which
represents a NSCLC subgroup of similar prevalence whose survival
has been upgraded by several years as a consequence of recent
remarkable progress with targeted therapy.4–6
This short review and consensus statement from the British
Thoracic Oncology Group (BTOG) and the Association of
Pulmonary Pathologists (APP) was produced through a process
of iterative review amongst members. A skeletal first article draft
suggesting main sub-headings was sent to APP and BTOG
members in February 2020. Feedback was received from co-
authors by April 2020, with re-draft based on their comments. All
authors declared themselves agreed with this version in June
2020. Members were also asked to highlight key articles that may
be missing from initial drafts.
Overall, we aim to (a) define the fundamental questions that
have limited progress in LCNEC to date, and (b) set out a
framework for the pursuit of translational and clinical progress in
the years to follow. At the heart of this ambition is a determination
to resolve the following fundamental questions:
1. What is large cell neuroendocrine lung carcinoma?
2. How many patients are affected by it?
3. What is standard of care treatment?
Unless these questions are answered conclusively, clinical
progress for patients with this cancer will continue to be limited.
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We will finish by describing a LCNEC ‘agenda for change’ to
answer these questions, including plans for a blinded review of
historical cases and a common registry of all LCNEC patients. It is
hoped that this approach will set solid foundations from which
LCNEC clinical trial proposals and treatment breakthroughs
emerge for future patient benefit.
WHAT IS LARGE CELL NEUROENDOCRINE LUNG CARCINOMA?
Although neuroendocrine differentiation in lung tumours has
been described in several papers since the 1970s, defining criteria
were first proposed in 1991.7 These have essentially remained the
same to the present day (WHO criteria). LCNEC has been classified
as a neuroendocrine carcinoma that appears to confer a SCLC
clinical phenotype.2 Its diagnostic challenges, especially in small
biopsy material, have presented a substantial problem to
pathologists over several years, creating a clinical context where
there is little confidence that LCNEC is being consistently labelled
as the same disease. This variability can be considered in terms of
both traditional histopathological assessment as well as modern
molecular pathological analysis, and is threatened even further by
an increasing emphasis on diagnostic optimisation using limited
pathological and cytological samples.8, 9
Histopathology
Although small biopsies and EBUS cytology specimens pro-
vide ~85% of lung cancer diagnoses in the UK and the majority
of cases internationally, many pathologists feel they are
unable to make a definitive LCNEC diagnosis without examination
of a resection specimen. Indeed, existing WHO LCNEC classifica-
tion cautions against definitive diagnosis unless a very
substantial excision biopsy or resection is available. The
difficulties posed by the histological classification are exemplified
in two phase 2 clinical trials that have focused on LCNEC,
both of which reclassified ~25% of recruited patients to an
alternative SCLC or NSCLC diagnosis following central pathological
review.10, 11
Current WHO criteria for LCNEC diagnosis include (i) neuroen-
docrine morphology (trabeculae, palisading, organoid nesting
and/or rosette formation), (ii) high proliferation rate (>10 mitoses
per 10 high-power fields), (iii) extensive geographic necrosis and
(iv) IHC expression of at least one neuroendocrine marker
(chromogranin-A, synaptophysin, NCAM/CD56) (Fig. 1). The
challenge of making this diagnosis is further complicated by the
fact that these criteria are used as a classification for two different
patterns of carcinoma. First, high-grade NSCLC showing morpho-
logical evidence of neuroendocrine differentiation and expressing
neuroendocrine markers. Second, lower-grade tumours resemble
an atypical carcinoid (AC) tumour, which, on closer inspection,
have a mitotic count of >10/2 mm2.
LCNEC is distinguished from SCLC via cytomorphological
assessment of cytoplasmic abundance, the presence of nucleoli
and nuclear size (Fig. 1).7 Assessment and interpretation of these
criteria may be difficult with cytology specimens or small biopsies
that can be crushed and morphologically heterogeneous, lacking
diagnostic architectural features (Fig. 2). Commonly samples are
labelled using alternative descriptive terms such as ‘combined
NSCLC/SCLC’, ‘NSCLC with neuroendocrine differentiation’ or
‘high grade neuroendocrine carcinoma’ rather than LCNEC, so
standardisation of this nomenclature will be of paramount
importance for progress. Parallel experience from the Dutch
pathology registry (PALGA) has suggested that an LCNEC
diagnosis from biopsy requires (i) NSCLC morphology devoid of
squamous or adenocarcinoma features, and (ii) positive staining
with IHC of ≥2 neuroendocrine markers (Fig. 1).12 This contrasts
with existing criteria from the WHO that recommends only ‘non-
small cell carcinoma, with neuroendocrine morphology and
immunophenotype, possible LCNEC'.13
In order to empower pathologists to facilitate future clinical
progress, we must (a) clarify what sample type is mandatory to
make a confident diagnosis, (b) define a common ‘one-size fits all’
diagnostic label for LCNEC that either excludes/includes cases of
‘combined SCLC/NSCLC’ and ‘NSCLC with neuroendocrine differ-




Fig. 1 Large cell neuroendocrine carcinoma. a Morphology showing cytoplasmic abundance, the presence of nucleoli and nuclear size
(haematoxylin and eosin, ×400). b–d immunohistochemistry: b CD56 (×200); c synaptophysin (×100); d Ki67 (×100).
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embrace several potential diagnostic groups, including those
where there is diagnostic doubt. One way to support a definition
may be to identify if overlapping molecular pathology exists
in cases that are difficult to label. Table 1 offers further speculation
on how LCNEC diagnostic criteria may develop over the coming
1–2 years. Central to these changes will be a supportive MDT
environment that harmonises the different elements of LCNEC
histology, imaging and presentation, facilitating further biopsy
and/or tumour resection when it is considered appropriate and in
the patient’s best interests. There now also exists an opportunity
to revisit the conventional histopathological diagnostic criteria for
LCNEC, refining its diagnosis using a combination of morpholo-
gical, immunohistochemical and molecular criteria.
Molecular pathology
Following on from a cluster of initial reports that were limited by
the patient number and/or scope of analysis,14–18 three sequen-
cing studies have offered large-scale molecular characterisation of
LCNECs, the methods and results of which are summarised in
Table 2.19–21 Methodological similarities between these studies
include relatively small patient numbers (range 45-78) and
concomitant sequencing/analysis of SCLC as a control cohort.
The most striking mutational results suggested a clear division of
LCNEC into ‘NSCLC-type’ and ‘SCLC-type’, a sub-classification
that could be made on the basis of RB1 and/or KRAS and/or
STK11/LKB1 mutation. These mutations have been frequently
identified in the Cancer Genome Atlas and other large-scale
genomic analyses as genetic hallmarks of NSCLC or SCLC.22 On the
face of it, these findings may corroborate the perception of
LCNEC as a ‘trans-differentiation’ phenomenon, implying that a
second biopsy at a spatially distinct region of the same tumour
would clarify a definitive NSCLC versus SCLC histology. However,
what emerged in the largest and most detailed sequencing study
was a transcriptional taxonomy suggestive that LCNEC is a
separate cancer entity, rather than a continuum of existing lung
cancer classifications; one that is closely aligned with SCLC, but
also featuring novel expression profiles and higher levels of
tumour mutational burden (TMB) than that seen in NSCLC or
SCLC.21
An important consideration with all this work is to avoid the
assumption that the presence of RB1 mutation or loss confirms a
SCLC phenotype—its contribution to NSCLC has been well char-
acterised.23 There also remains a strong argument that three
additional and well established immunohistochemical tests (RB1,
p16, LKB1) may suffice to categorise LCNEC into ‘SCLC-type’ and
‘NSCLC-type’ spectrums, should these sub-classifications be
deemed suitable for further clinical trial interrogation.24, 25 More-
over, reports of prolonged responses to tyrosine kinase inhibitors
in LCNEC harbouring EGFR mutations or ALK rearrangements
suggest that standard of care molecular testing can still offer
significant benefits to a finite group of patients26–28; whether
these cases represent those LCNECs that are mixed with
adenocarcinoma is difficult to establish. Molecular overlap of
ACs and LCNECs has also been identified, whereby a small number
of tumours with histological features of AC can, in particular,
adopt TP53+/− RB1 mutations that are associated with poorer
outcomes.29–31 Finally, those involved in standardisation of the
future diagnostic process must closely consider which sequencing
techniques will be feasible with small samples and require
integration into molecular pathology labs. The current crop of
data suggests that exome and transcriptomic sequencing must at
least be considered, although it is unclear at this point if this will
help resolve differences or confuse things further.
HOW MANY PATIENTS ARE AFFECTED BY LCNEC?
An implicit aspect of answering this question definitively will be a
resolution to question one above: a conclusive set of LCNEC
diagnostic criteria. Thus, we can only broadly estimate LCNEC
patient numbers at present, and there currently exists no data
capture of LCNEC cases in the UK National Lung Cancer Audit
(NLCA). Existing international data suggest it accounts for 2–3% of
lung cancer cases, a considerable number of patients given the
high global incidence of lung cancer.2, 32 With a projected 46,000
a b
Fig. 2 Architectural quality of biopsy versus resection specimens. a Small cell lung cancer biopsy showing crushing and loss of architecture
(haematoxylin and eosin, ×200). b Small cell lung cancer resection sample (haematoxylin and eosin, ×400). Images provided by Dr Anna Paterson.
Table 1. Possible future criteria for LCNEC definition.
Resection samplesa Small biopsy samplesa
1. LCNEC (+/− combined adenocarcinoma +/− combined SCLC).
2. LC carcinoma with NE differentiation.
3. LC carcinoma with NE morphology.
1. LCNEC (only rare cases with sufficient sample).
2. ‘Probable’ LCNEC, NSCLC + NE morphology and/or NE markers.
3. High grade NE carcinoma (HGNEC) NOS (i.e. could be SCLC or LCNEC).
LCNEC large cell neuroendocrine carcinoma, LC large cell, NE neuroendocrine, NOS not otherwise specified, SCLC small cell lung cancer, NSCC non-small cell
carcinoma.
aWhere possible, Rb1/p16 IHC and targeted NGS to be performed for the purpose of further prospective scrutiny.
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new cases of lung cancer cases in the UK per annum, we estimate
that ~1000–1500 patients could be diagnosed with LCNEC each
year, ~75% of whom will present at an advanced stage. For
~229,000 new lung cancer cases per annum in the US, we
estimate 4500–7000 will be diagnosed with LCNEC. Thus, there
exists no good reason, as far as patient numbers are concerned, to
consider recruitment to LCNEC clinical trials as ‘unachievable’. By
comparison, ALK-rearranged NSCLC patients represent a simi-
lar sized lung cancer subgroup and have been the basis of
pioneering international randomised phase 3 trials involving up to
343 patients.4–6 The main contrast between LCNEC and ALK
subgroups is that the latter currently represents an easily
identifiable subtype, readily diagnosed using small biopsies.
Diagnostic uncertainty also means we are likely underestimating
the true percentage of LCNEC cases, and there may be
unestablished disparities in LCNEC incidence between early and
advanced disease. Using the example of ALK as a paradigm for
‘rare’ lung cancer clinical research, potential opportunities for
further trial development in LCNEC will be the International Rare
Cancer Initiative (IRCI) affiliated with the UK National Institute for
Health Research (NIHR) and Cancer Research UK, the European
Reference Networks (ERNs) created to deal with rare tumours, and
the European Organisation for Research and Treatment of Cancer
(EORTC) which can be used as a platform for data registration and
clinical studies.
WHAT IS THE STANDARD OF CARE TREATMENT?
As with question 2, a complete answer to this question will
ultimately follow on from a definitive LCNEC definition. For our
day-to-day practice, the lung cancer community will remain
unclear on the best choice of routine treatment unless there is an
acceptable and reproducible pathological consensus on criteria
for the classification of LCNEC in small diagnostic biopsy and
cytology samples. If it is concluded that LCNEC is separate from
other subtypes of NSCLC or SCLC, it can also be reasonably argued
that no standard of care (SOC) exists due to an absence of phase 3
and/or randomised clinical trials. In turn, there would be a
justifiable niche for first line clinical trial proposals given the very
modest clinical benefits that have been observed in the
prospective setting using chemotherapy.
In view of these data limitations, an informative body of
retrospective and real-world data has been accumulated over a
number of years by colleagues in the US and the Netherlands. In
early stage disease, surgical resection is the preferred treatment,33
with results from over 6000 stage I–IIIA patients included in the US
National Cancer Database demonstrating superior survival vs.
stereotactic radiation or chemoradiotherapy.34 Review of 1672
patients included in this database suggested LCNEC is the only
subtype of NSCLC which could benefit from adjuvant chemother-
apy at all operable stages (IA–IIIA).35 In its advanced stages,
experience from the Dutch PALGA network have suggested that
NSCLC-based combinations (platinum-gemcitabine/taxanes) may
perform better than traditional platinum-etoposide approaches,
particularly in ‘NSCLC-type’ cases expressing wild-type Rb1.25, 36
Such an approach suggests LCNEC could be optimised by a
precision medicine optimisation for treatment stratification,
whether it be with novel agents or traditional chemotherapies.
Existing/limited prospective clinical trial evidence includes two
prospective single arm phase 2 trials examining the combination
of cisplatin-etoposide or cisplatin-irinotecan in 42 and 44
advanced-stage patients, respectively.10, 11 Median overall survival
(OS) with these treatments was 7.7 months (95% CI, 6–9.6)
vs.15.1 months (95% CI, 11.2–19), respectively. After a centralised
pathology review of 41 patients who received cisplatin-irinotecan,
10 were reclassified to SCLC and 1 to NSCLC. Median survival time
was 12.6 months (95% CI, 9.3–16.0) in the LCNEC group vs.
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When combined ~25% of patients in both studies were
reclassified to an alternative diagnosis (mostly SCLC) following
central pathological review. More recently, the addition of
everolimus to paclitaxel and carboplatin in a phase 2 study of
49 LCNEC patients led to a median OS of 9.9 months and a 51%
incidence of grade 3–4 toxicities.37
A final inescapable question in the current NSCLC treatment
landscape is whether LCNEC could be vulnerable to treatment with
immune checkpoint inhibitors (ICIs). Despite being characterised as
having low levels of PD-L1 positivity, preliminary data from the US
have suggested response rates to ICIs are perhaps above what
might have been expected for a low PD-L1 cancer, particularly in
‘SCLC-type’ disease.38 Given the high TMB suggested, LCNEC may
yet represent a relatively unique cancer histology where TMB
proves far more informative than PD-L1 IHC for prediction of ICI
benefit.19, 39 It should however be noted that the role of TMB as a
biomarker for ICI remains a contentious one, with studies including
CheckMate-227 identifying that it may not be predictive of survival
benefit.39 Of LCNEC patients who are resistant to ICIs, one might
predict that their cancers are ‘NSCLC-type’ LCNEC harbouring
STK11 mutation, a mutation in NSCLC which has been strongly
associated with ICI resistance.40 A number of key questions will
require UK, European and international consensus on treatment
strategy once pathological criteria have been agreed, for instance
(i) should we offer SCLC-based chemotherapy if RB1 mutation or
loss is established, and (ii) should we also offer prophylactic cranial
irradiation to these cases?
FORGING A PATH FORWARD
Below we propose a series of practical steps for optimising
management and treatment approaches in LCNEC, with a view to
establishing foundations for further clinical trial work.
1. Establishing an LCNEC definition
i. Blinded inter-centre assessment of candidate LCNECs. A
network of APP pathologists will receive tissue blocks from
resection and biopsy samples for the following NSCLC
classifications: LCNEC, SCLC, combined SCLC/ NSCLC,
combined LCNEC/ NSCLC, ACs with high mitotic count
and NSCLC with neuroendocrine morphology (+/− NE IHC
positivity). Their analyses and interpretation of sections will
be blinded, and they will be asked whether the sample is
deemed to be of sufficient quality for making a definitive
diagnosis. Where possible, paired samples (biopsy/resec-
tion) will be assessed. Targeted sequencing results for each
sample will be made available following initial histopatho-
logical review, with each pathologist being asked if they
would revise any of their conclusions on the basis of this
updated molecular detail. All work will be preceded by a
consensus choice of nomenclature and an agreed strategy
for interpreting molecular data.
ii. Spatial heterogeneity. A small number of LCNECs have
been sequenced in the Cancer Research UK (CRUK)
TRACERx programme,41 offering the potential to assess
whether LCNEC represents a trans-differentiation state
between NSCLC and SCLC. Exomic profiles will be examined
from spatially distinct regions of resected tumours. The
postmortem PEACE study and recurrence samples from
TRACERx represent a possible further opportunity to detail
these changes. An anticipated small number of samples
means that it will be challenging to validate any insight
gained in the more common setting of advanced LCNEC,
leaving this exploration more likely to remain in the realm
of discovery rather than translational research.Overall,
completion of this work should be facilitated by the recent
roll-out of a common infrastructure for molecular testing in
NHS England, with a drive towards routine next generation
sequencing coinciding with the creation of seven genomics
laboratory hubs across England.
2. Establishing the true incidence of LCNEC.All true LCNEC lung
cases will be ultimately documented in the National Lung
Cancer Audit (NLCA).42 Depending on the results of the
work proposed above, this definition may be revised
following completion of multi-site pathology review.
3. Establishing standard of care treatment and facilitating
future clinical trials.
i. An up-to-date anonymised registry of LCNEC cases will
be compiled and updated, documenting pathological,
immunohistochemical, surgical resection status (R0, R1,
R2, R uncertain), systemic treatment, morbidity, relapse-
free survival and overall survival details. Quarterly TCs
will review challenging cases from this series. Retro-
spective outcomes in early and advanced disease will be
assessed after a sufficient period of follow-up.
ii. For advanced stage, stratification of chemotherapy using
Rb1 and p16 immunohistochemistry should be considered,
in line with the approach described by the Netherlands.
iii. On the basis of previously described US data, adjuvant
treatment should be considered in all LCNEC patients
following resection.35 Choice of chemotherapy in this
setting will require consensus, but may also be stratified
according to Rb1 and p16 status. Given there is firmer
ground for diagnosing LCNEC using resection tissue, it is
feasible to consider a clinical trial of adjuvant chemotherapy
for stage I disease.
iv. In the medium-term, use the foundations of the work
proposed above as a renewed basis for clinical trial
proposals in late stage disease. Similar to recent break-
throughs in targeting KRAS-mutant NSCLC, emerging
knowledge in the treatment of LCNEC offers the possibility
for a significant impact on patient care.43
CONCLUSIONS
The steps we have proposed in this article represent an iterative
and rational path forward towards clinical breakthroughs that can
be modelled on success in other lung cancer pathologies. Progress
will likely be measured in 3–5-year intervals given there are no
quick solutions to some of the difficulties discussed. However, the
appetite amongst the lung cancer community to remedy this
unmet need remains without question.
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